Annual Drug Patent Expirations for INLYTA
Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for INLYTA.
This drug has one hundred and twenty-four patent family members in fifty-six countries.
The generic ingredient in INLYTA is axitinib. Two suppliers are listed for this compound. Additional details are available on the axitinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
